Navega Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Navega Therapeutics is a privately held, early-stage biotechnology company based in San Diego, California, focused on developing epigenetic gene therapies to treat chronic pain. The company has developed a patented, non-permanent gene therapy intended to be non-addictive, highly specific, and long-lasting for pain. Its approach is inspired by natural human mutations associated with reduced pain perception, and preclinical mouse studies have shown increased pain tolerance while preserving sensitivity to mechanical stimulation.

Chronic pain affects a large patient population, and conventional treatments predominantly rely on opioid narcotics. In March 2024, Navega announced a collaboration with Charles River Laboratories to advance an AAV9 production program, representing a concrete step in its development.

Get verified Navega Therapeutics emails free

Company overview Employee directory